<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02246504</url>
  </required_header>
  <id_info>
    <org_study_id>HIFU/BG/NT</org_study_id>
    <nct_id>NCT02246504</nct_id>
  </id_info>
  <brief_title>Registry - Use of a High Intensity Focused Ultrasound (HIFU) in Patients With Non-malignant Thyroid Nodules.</brief_title>
  <official_title>Registry - Use of a High Intensity Focused Ultrasound (HIFU) in Patients With Non-malignant Thyroid Nodules.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theraclion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Theraclion</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate thyroid nodule's volume, structure and
      vascularisation changes following HIFU therapy assessed by ultrasonography
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HIFU treatment will be performed under conscious sedation under the supervision /
      responsibilities of an anesthetist.

      A maximum of 2 HIFU sessions per nodule will be performed per patient. The decision to
      retreat the patient will be taken at 1 month post-HIFU or later.

      Follow-up after HIFU treatment

      D1 after HIFU session:

        -  Indirect laryngoscopy to check vocal cord mobility.

      D7 after HIFU session

        -  Clinical examination (skin, local symptoms, oedema, voice….),

        -  Ultrasonography and Power Doppler,

      M1 after HIFU session

        -  Clinical examination (skin, local symptoms, oedema, voice….),

        -  Ultrasonography and Power Doppler,

      M3 after HIFU session

        -  Clinical examination (skin, local symptoms, oedema, voice….),

        -  Ultrasonography and Power Doppler Decision for an additional HIFU course to improve
           volume reduction.

      In case of a second HIFU session D7b, M1b and M3b will be performed

      M6 after last HIFU session

        -  Clinical examination (skin, local symptoms, oedema, voice….),

        -  Ultrasonography and Power Doppler

        -  TSH

        -  Free T4

        -  Antithyroid peroxidase antibodies

        -  Calcemia and PTH (in case of bilateral treatment or in case previous thyroid surgery)

      M9 after HIFU session

        -  Clinical examination (skin, local symptoms, oedema, voice….),

        -  Ultrasonography and Power Doppler

      M12 after last HIFU session

        -  Clinical examination (skin, local symptoms, oedema, voice….),

        -  Ultrasonography and Power Doppler

        -  TSH

        -  Free T4

        -  Antithyroid peroxidase antibodies

        -  Calcemia and PTH (in case of bilateral treatment or in case previous thyroid surgery)

      M18, M24, M36 after HIFU session

        -  Clinical examination (skin, local symptoms, oedema, voice….),

        -  Ultrasonography and Power Doppler
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 9, 2012</start_date>
  <completion_date type="Actual">March 7, 2017</completion_date>
  <primary_completion_date type="Actual">March 7, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in thyroid nodule's volume</measure>
    <time_frame>Month 6</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in thyroid nodule's structure and vascularisation</measure>
    <time_frame>Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>D1, D7, M1, M3 and M6</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Non-malignant Thyroid Nodule</condition>
  <arm_group>
    <arm_group_label>HIFU treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>use of HIFU treatment in patients with non-malignant thyroid nodules</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HIFU treatment</intervention_name>
    <arm_group_label>HIFU treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patient 18 years or older.

          -  Patient presenting with at least one thyroid nodule with no signs of malignancy:

               1. Non suspect clinically and at ultrasonography imaging

               2. Benign cytological diagnosis at FNAB from the last 6 months

               3. Normal serum calcitonin

               4. No history of neck irradiation

          -  Normal TSH.

          -  Targeted nodule accessible and eligible to HIFU

          -  Absence of abnormal vocal cord mobility at laryngoscopy.

          -  Nodule diameter ≥ 10mm measured by ultrasound.

          -  Composition of the targeted nodule(s) : no more than 30% cystic

        Exclusion Criteria:

          -  Head and/or neck disease that prevents hyperextension of neck.

          -  Known history of thyroid cancer or other neoplasias in the neck region.

          -  History of neck irradiation.

          -  Macrocalcification inducing a shadow in the thyroid significant enough to preclude the
             HIFU treatment

          -  Posterior position of the nodule if the thickness of the nodule is &lt;15mm

          -  Pregnant or lactating woman

          -  Any contraindication to IV neurolept analgesia.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roussanka Kovatcheva, Prof.</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <location>
    <facility>
      <name>Clinic of thyroid and metabolite bone disease of the Acad. of Ivan Penchev UDHATE - 2, Zdrave street</name>
      <address>
        <city>Sofia</city>
        <zip>14031</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 16, 2014</study_first_submitted>
  <study_first_submitted_qc>September 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2014</study_first_posted>
  <last_update_submitted>May 25, 2018</last_update_submitted>
  <last_update_submitted_qc>May 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Diseases</mesh_term>
    <mesh_term>Thyroid Nodule</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

